ProCE Banner Activity

An Expert’s Guide to ASCO 2021: A Preview of the Top Abstracts

Conference Coverage
Clinical Thought
Experts highlight key studies being presented at the upcoming 2021 ASCO virtual meeting. The CCO ASCO Virtual Conference Coverage program will have the information you need to understand and integrate the latest oncology data into your practice.

Released: June 02, 2021

Share

Faculty

Michael A. Davies

Michael A. Davies, MD, PhD

Professor and Chair, Department of Melanoma Medical Oncology
Professor, Translational Molecular Pathology and Genomic Medicine
Anne and John Mendelsohn Chair in Cancer Research
University of Texas, MD Anderson Cancer Center
Houston, Texas

Ian W. Flinn

Ian W. Flinn, MD, PhD

Chief Scientific Officer
One Oncology and Tennessee Oncology
Nashville, Tennesse

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Evan J. Lipson

Evan J. Lipson, MD

Associate Professor of Oncology
Melanoma and Cancer Immunology Programs
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Daniel P. Petrylak

Daniel P. Petrylak, MD

Professor of Medicine
Smilow Cancer Center
Yale University Medical Center
New Haven, Connecticut

Zofia Piotrowska

Zofia Piotrowska, MD

Assistant Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Elizabeth Plimack

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Karen L. Reckamp

Karen L. Reckamp, MD, MS

Associate Professor
Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, California

Manish A. Shah

Manish A. Shah, MD

Assistant Member, Department of Medicine, Gastrointestinal Oncology
Memorial Sloan-Kettering Cancer Center
Attending Physician, Department of Medicine, Division of Solidy Tumor Oncology
Memorial Hospital
New York, New York

Eunice S. Wang

Eunice S. Wang, MD

Chief, Leukemia/Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme

Faculty Disclosure

Primary Author

Michael A. Davies, MD, PhD

Professor and Chair, Department of Melanoma Medical Oncology
Professor, Translational Molecular Pathology and Genomic Medicine
Anne and John Mendelsohn Chair in Cancer Research
University of Texas, MD Anderson Cancer Center
Houston, Texas

Michael A. Davies, MD, PhD, has disclosed that he has received consulting fees from ABM Therapeutics, Apexigen, Array, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Pfizer, Roche/Genentech, Sanofi, and Vaccinex.

Ian W. Flinn, MD, PhD

Chief Scientific Officer
One Oncology and Tennessee Oncology
Nashville, Tennesse

Ian W. Flinn, MD, PhD, has disclosed that he has received consulting fees from AbbVie, AstraZeneca, BeiGene, Genentech, Gilead Sciences, Great Point Partners, Iksuda, Janssen, Juno, Kite, MorphoSys, Novartis, Nurix, Roche, Seagen, Takeda, TG Therapeutics, Unum Therapeutics, Verastem, Vincerx, and Yingli and research support from AbbVie, Acerta, Agios, ArQule, AstraZeneca, BeiGene, Calithera, Celgene, Constellation, Curis, Forma, Forty Seven, Genentech, Gilead Sciences, IGM Biosciences, Incyte, Infinity, Janssen, Juno, Karyopharm, Kite, Loxo, Merck, MorphoSys, Novartis, Pfizer, Portola, Rhizen, Roche, Seagen, Takeda, Teva, TG Therapeutics, Trillium, Triphase Research & Development Corp, Unum Therapeutics, and Verastem.

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji K. Kumar, MD has disclosed that he has received consulting fees from AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Oncopeptides, and Takeda and research support from AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Janssen, MedImmune, Oncopeptides, Takeda, and TeneoBio.

Evan J. Lipson, MD

Associate Professor of Oncology
Melanoma and Cancer Immunology Programs
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Evan J. Lipson, MD, has disclosed that he has received consulting fees from Array, Bristol-Myers Squibb, EMD Serono, MacroGenics, Merck, Novartis, Odonate, Regeneron, and Sanofi and funds for research support paid to his institution from Bristol-Myers Squibb, Merck, Regeneron, and Sanofi.

Daniel P. Petrylak, MD

Professor of Medicine
Smilow Cancer Center
Yale University Medical Center
New Haven, Connecticut

Daniel P. Petrylak, MD, has disclosed that he has received consulting fees from Ada Cap (Advanced Accelerator Applications), Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis Oncology, Exelixis, Incyte, Janssen, Lilly, Mirati, Monopteros, Pfizer, Pharmacyclics, Roche, Seattle Genetics, and Urogen; has received funds for research support paid to his institution from Ada Cap (Advanced Accelerator Applications), Agensys, Astellas, AstraZeneca, Bayer, BioXcel, Bristol-Myers Squibb, Clovis Oncology, Eisai, Endocyte, Genentech, Innocrin, Lilly, MedImmune, Medivation, Merck, Mirati, Novartis, Pfizer, Progenics, Replimune, Roche, Sanofi, and Seattle Genetics; and has had ownership interest in Bellicum and Tyme.

Zofia Piotrowska, MD

Assistant Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Zofia Piotrowska, MD, MHS, has disclosed that she has received consulting fees from AstraZeneca, Blueprint Medicines, C4 Therapeutics, Genentech, Incyte, Janssen, Jazz, Lilly, Medtronic, and Takeda and funds for research support from AbbVie, AstraZeneca, Cullinan Oncology, Daiichi Sankyo, Janssen, Novartis, Spectrum, Takeda, and Tesaro.

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Elizabeth R. Plimack, MD, MS, has disclosed that she has received funds for research support from AstraZeneca, Bristol-Myers Squibb, Genentech, and Merck and consulting fees from AstraZeneca, Bristol-Myers Squibb, Calithera, Flatiron, Genentech, Infinity, Janssen, MEI, Merck, Pfizer, and Seattle Genetics.

Karen L. Reckamp, MD, MS

Associate Professor
Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, California

Karen L. Reckamp, MD, MS, has disclosed that she has received consulting fees from AstraZeneca, Boehringer Ingelheim, Calithera, Genentech, Guardant, Precision Health, and Tesaro and funds for research support paid to her prior institution from AbbVie, Acea, Adaptimmune, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Guardant, Janssen, Loxo Oncology, Molecular Partners, Seattle Genetics, Spectrum, Takeda, Xcovery, and Zeno.

Manish A. Shah, MD

Assistant Member, Department of Medicine, Gastrointestinal Oncology
Memorial Sloan-Kettering Cancer Center
Attending Physician, Department of Medicine, Division of Solidy Tumor Oncology
Memorial Hospital
New York, New York

Manish A. Shah, MD, has disclosed that he has received consulting fees from Astellas, Bristol-Myers Squibb, and Merck.

Eunice S. Wang, MD

Chief, Leukemia/Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Eunice S. Wang, MD, has disclosed that she has received consulting fees from Mana; has served on the advisory board for AbbVie, Astellas, Bristol-Myers Squibb/Celgene, Genentech, Gilead Sciences, GlaxoSmithKline, Jazz, Kite, Kura Oncology, Novartis, Pfizer, Stemline, and Takeda; and has received fees for non-CME/CE services from Dava Oncology, Kura, Pfizer, and Stemline.